prazosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihypertensive substances, prazosin derivatives | 4209 | 19216-56-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 1.40 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.49 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 68 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.73 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 4.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 1976 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Atrioventricular block first degree | 108.13 | 16.06 | 37 | 6505 | 7236 | 63475244 |
| Completed suicide | 74.30 | 16.06 | 83 | 6459 | 145590 | 63336890 |
| Suicidal ideation | 53.04 | 16.06 | 47 | 6495 | 62374 | 63420106 |
| Toxicity to various agents | 51.95 | 16.06 | 92 | 6450 | 247158 | 63235322 |
| Unmasking of previously unidentified disease | 50.32 | 16.06 | 13 | 6529 | 963 | 63481517 |
| Electrocardiogram ST segment elevation | 43.26 | 16.06 | 16 | 6526 | 3911 | 63478569 |
| Electrocardiogram repolarisation abnormality | 41.93 | 16.06 | 12 | 6530 | 1305 | 63481175 |
| Sinus bradycardia | 41.34 | 16.06 | 23 | 6519 | 14528 | 63467952 |
| Norepinephrine increased | 41.26 | 16.06 | 7 | 6535 | 62 | 63482418 |
| Circulatory collapse | 39.81 | 16.06 | 26 | 6516 | 21912 | 63460568 |
| Systolic dysfunction | 39.63 | 16.06 | 12 | 6530 | 1587 | 63480893 |
| Posterior reversible encephalopathy syndrome | 37.58 | 16.06 | 23 | 6519 | 17322 | 63465158 |
| Cardiac arrest | 34.45 | 16.06 | 45 | 6497 | 92500 | 63389980 |
| Electrocardiogram QRS complex prolonged | 33.62 | 16.06 | 15 | 6527 | 5923 | 63476557 |
| Cardio-respiratory arrest | 31.94 | 16.06 | 35 | 6507 | 59924 | 63422556 |
| Sinus tachycardia | 30.57 | 16.06 | 23 | 6519 | 24245 | 63458235 |
| Ventricular hypokinesia | 30.42 | 16.06 | 13 | 6529 | 4631 | 63477849 |
| Drug withdrawal syndrome | 28.25 | 16.06 | 23 | 6519 | 27171 | 63455309 |
| Hypotension | 26.92 | 16.06 | 75 | 6467 | 272529 | 63209951 |
| Depression | 26.65 | 16.06 | 61 | 6481 | 196431 | 63286049 |
| Cardiac hypertrophy | 26.58 | 16.06 | 8 | 6534 | 1037 | 63481443 |
| Suspected suicide | 26.11 | 16.06 | 13 | 6529 | 6555 | 63475925 |
| Intentional overdose | 25.96 | 16.06 | 35 | 6507 | 74117 | 63408363 |
| Hypertrichosis | 25.79 | 16.06 | 8 | 6534 | 1146 | 63481334 |
| Cardiotoxicity | 25.79 | 16.06 | 14 | 6528 | 8424 | 63474056 |
| Post-traumatic stress disorder | 25.74 | 16.06 | 12 | 6530 | 5239 | 63477241 |
| Overdose | 25.63 | 16.06 | 44 | 6498 | 115034 | 63367446 |
| Metabolic acidosis | 23.47 | 16.06 | 26 | 6516 | 45043 | 63437437 |
| Withdrawal syndrome | 23.09 | 16.06 | 18 | 6524 | 19979 | 63462501 |
| Phaeochromocytoma | 22.38 | 16.06 | 6 | 6536 | 513 | 63481967 |
| Electrocardiogram QT prolonged | 22.22 | 16.06 | 29 | 6513 | 59501 | 63422979 |
| Ventricular extrasystoles | 21.56 | 16.06 | 14 | 6528 | 11673 | 63470807 |
| Myasthenic syndrome | 21.17 | 16.06 | 5 | 6537 | 255 | 63482225 |
| Renal papillary necrosis | 20.88 | 16.06 | 5 | 6537 | 271 | 63482209 |
| Status epilepticus | 20.44 | 16.06 | 15 | 6527 | 15218 | 63467262 |
| Dissociative identity disorder | 20.41 | 16.06 | 4 | 6538 | 83 | 63482397 |
| Blood prolactin increased | 20.31 | 16.06 | 9 | 6533 | 3494 | 63478986 |
| Antipsychotic drug level decreased | 19.66 | 16.06 | 5 | 6537 | 348 | 63482132 |
| Drug intolerance | 19.57 | 16.06 | 4 | 6538 | 308657 | 63173823 |
| Anxiety | 18.71 | 16.06 | 57 | 6485 | 217484 | 63264996 |
| Alcoholism | 18.54 | 16.06 | 7 | 6535 | 1811 | 63480669 |
| Electrocardiogram QRS complex shortened | 18.25 | 16.06 | 5 | 6537 | 464 | 63482016 |
| Occipital neuralgia | 18.08 | 16.06 | 5 | 6537 | 480 | 63482000 |
| Haemophagocytic lymphohistiocytosis | 17.83 | 16.06 | 12 | 6530 | 10615 | 63471865 |
| Joint swelling | 17.46 | 16.06 | 6 | 6536 | 327660 | 63154820 |
| Coma scale abnormal | 17.01 | 16.06 | 9 | 6533 | 5144 | 63477336 |
| Hypertensive encephalopathy | 16.73 | 16.06 | 5 | 6537 | 633 | 63481847 |
| Activation syndrome | 16.68 | 16.06 | 4 | 6538 | 218 | 63482262 |
| Stress cardiomyopathy | 16.65 | 16.06 | 11 | 6531 | 9439 | 63473041 |
| Thyroxine free decreased | 16.28 | 16.06 | 5 | 6537 | 693 | 63481787 |
| Cardiogenic shock | 16.21 | 16.06 | 14 | 6528 | 17918 | 63464562 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Antidepressant drug level above therapeutic | 107.26 | 17.20 | 20 | 4898 | 226 | 34951787 |
| Analgesic drug level above therapeutic | 102.46 | 17.20 | 20 | 4898 | 293 | 34951720 |
| Parasomnia | 74.33 | 17.20 | 16 | 4902 | 388 | 34951625 |
| Priapism | 65.06 | 17.20 | 25 | 4893 | 4969 | 34947044 |
| Sudden cardiac death | 53.53 | 17.20 | 20 | 4898 | 3681 | 34948332 |
| Serotonin syndrome | 51.25 | 17.20 | 33 | 4885 | 19900 | 34932113 |
| Abnormal sleep-related event | 50.07 | 17.20 | 12 | 4906 | 475 | 34951538 |
| Suicidal behaviour | 49.22 | 17.20 | 15 | 4903 | 1482 | 34950531 |
| Vasoplegia syndrome | 38.08 | 17.20 | 13 | 4905 | 1843 | 34950170 |
| Drug interaction | 35.80 | 17.20 | 90 | 4828 | 225856 | 34726157 |
| Suicidal ideation | 34.40 | 17.20 | 35 | 4883 | 40353 | 34911660 |
| Blood pressure ambulatory increased | 32.84 | 17.20 | 6 | 4912 | 60 | 34951953 |
| Cardiac autonomic neuropathy | 32.57 | 17.20 | 6 | 4912 | 63 | 34951950 |
| Somnambulism | 31.70 | 17.20 | 13 | 4905 | 3059 | 34948954 |
| Pulmonary congestion | 31.03 | 17.20 | 21 | 4897 | 13744 | 34938269 |
| Tri-iodothyronine decreased | 28.97 | 17.20 | 6 | 4912 | 120 | 34951893 |
| Non-high-density lipoprotein cholesterol increased | 28.25 | 17.20 | 6 | 4912 | 136 | 34951877 |
| Supine hypertension | 27.58 | 17.20 | 7 | 4911 | 352 | 34951661 |
| Lactic acidosis | 27.56 | 17.20 | 29 | 4889 | 34743 | 34917270 |
| Globulins increased | 26.83 | 17.20 | 7 | 4911 | 393 | 34951620 |
| Thyroxine decreased | 25.66 | 17.20 | 6 | 4912 | 213 | 34951800 |
| Compartment syndrome | 25.24 | 17.20 | 11 | 4907 | 3007 | 34949006 |
| Sinus bradycardia | 25.06 | 17.20 | 18 | 4900 | 12945 | 34939068 |
| Sleep disorder | 24.35 | 17.20 | 26 | 4892 | 31662 | 34920351 |
| Spleen tuberculosis | 23.99 | 17.20 | 4 | 4914 | 22 | 34951991 |
| Electrocardiogram QT prolonged | 23.68 | 17.20 | 29 | 4889 | 40923 | 34911090 |
| Rhabdomyolysis | 22.63 | 17.20 | 37 | 4881 | 68126 | 34883887 |
| Overdose | 21.97 | 17.20 | 43 | 4875 | 91016 | 34860997 |
| Left atrial dilatation | 19.08 | 17.20 | 8 | 4910 | 1988 | 34950025 |
| Hyperlactacidaemia | 18.92 | 17.20 | 9 | 4909 | 3007 | 34949006 |
| Troponin T increased | 17.76 | 17.20 | 8 | 4910 | 2363 | 34949650 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Analgesic drug level above therapeutic | 96.13 | 14.11 | 20 | 9830 | 469 | 79734069 |
| Antidepressant drug level above therapeutic | 89.68 | 14.11 | 20 | 9830 | 656 | 79733882 |
| Atrioventricular block first degree | 88.58 | 14.11 | 39 | 9811 | 12452 | 79722086 |
| Completed suicide | 78.49 | 14.11 | 122 | 9728 | 245645 | 79488893 |
| Parasomnia | 76.63 | 14.11 | 17 | 9833 | 544 | 79733994 |
| Priapism | 70.71 | 14.11 | 25 | 9825 | 4480 | 79730058 |
| Sinus bradycardia | 67.82 | 14.11 | 41 | 9809 | 25206 | 79709332 |
| Sudden cardiac death | 49.34 | 14.11 | 20 | 9830 | 5205 | 79729333 |
| Posterior reversible encephalopathy syndrome | 49.16 | 14.11 | 34 | 9816 | 26247 | 79708291 |
| Electrocardiogram QT prolonged | 48.84 | 14.11 | 58 | 9792 | 90328 | 79644210 |
| Overdose | 44.78 | 14.11 | 81 | 9769 | 184125 | 79550413 |
| Systolic dysfunction | 44.53 | 14.11 | 17 | 9833 | 3778 | 79730760 |
| Abnormal sleep-related event | 44.44 | 14.11 | 12 | 9838 | 877 | 79733661 |
| Hypotension | 43.38 | 14.11 | 136 | 9714 | 440181 | 79294357 |
| Suicidal ideation | 42.92 | 14.11 | 50 | 9800 | 76290 | 79658248 |
| Drug interaction | 42.52 | 14.11 | 130 | 9720 | 415053 | 79319485 |
| Suicidal behaviour | 39.74 | 14.11 | 15 | 9835 | 3232 | 79731306 |
| Suspected suicide | 38.65 | 14.11 | 21 | 9829 | 10555 | 79723983 |
| Unmasking of previously unidentified disease | 38.42 | 14.11 | 13 | 9837 | 2044 | 79732494 |
| Norepinephrine increased | 37.98 | 14.11 | 7 | 9843 | 85 | 79734453 |
| Toxicity to various agents | 35.93 | 14.11 | 124 | 9726 | 421416 | 79313122 |
| Electrocardiogram repolarisation abnormality | 33.38 | 14.11 | 12 | 9838 | 2255 | 79732283 |
| Cardiac autonomic neuropathy | 33.27 | 14.11 | 6 | 9844 | 64 | 79734474 |
| Blood pressure ambulatory increased | 33.27 | 14.11 | 6 | 9844 | 64 | 79734474 |
| Serotonin syndrome | 33.16 | 14.11 | 34 | 9816 | 44993 | 79689545 |
| Electrocardiogram ST segment elevation | 31.59 | 14.11 | 17 | 9833 | 8380 | 79726158 |
| Lactic acidosis | 31.35 | 14.11 | 41 | 9809 | 70318 | 79664220 |
| Vasoplegia syndrome | 31.23 | 14.11 | 13 | 9837 | 3617 | 79730921 |
| Pulmonary congestion | 28.64 | 14.11 | 25 | 9825 | 27075 | 79707463 |
| Somnambulism | 28.52 | 14.11 | 14 | 9836 | 5707 | 79728831 |
| Supine hypertension | 27.32 | 14.11 | 7 | 9843 | 417 | 79734121 |
| Cardiac hypertrophy | 25.41 | 14.11 | 9 | 9841 | 1621 | 79732917 |
| Ventricular hypokinesia | 24.73 | 14.11 | 15 | 9835 | 9264 | 79725274 |
| Alcoholism | 24.39 | 14.11 | 11 | 9839 | 3712 | 79730826 |
| Cardio-respiratory arrest | 24.18 | 14.11 | 46 | 9804 | 108464 | 79626074 |
| Compartment syndrome | 24.04 | 14.11 | 12 | 9838 | 5070 | 79729468 |
| Antipsychotic drug level decreased | 23.90 | 14.11 | 8 | 9842 | 1216 | 79733322 |
| Sinus tachycardia | 23.85 | 14.11 | 26 | 9824 | 36882 | 79697656 |
| Cardiac arrest | 23.59 | 14.11 | 60 | 9790 | 172036 | 79562502 |
| Hypertrichosis | 23.54 | 14.11 | 8 | 9842 | 1274 | 79733264 |
| Circulatory collapse | 23.41 | 14.11 | 26 | 9824 | 37642 | 79696896 |
| Drug withdrawal syndrome | 23.38 | 14.11 | 25 | 9825 | 34693 | 79699845 |
| Spleen tuberculosis | 23.10 | 14.11 | 4 | 9846 | 33 | 79734505 |
| Joint swelling | 22.95 | 14.11 | 4 | 9846 | 288642 | 79445896 |
| Electrocardiogram QRS complex prolonged | 22.60 | 14.11 | 15 | 9835 | 10818 | 79723720 |
| Withdrawal syndrome | 21.09 | 14.11 | 21 | 9829 | 26833 | 79707705 |
| Tardive dyskinesia | 20.53 | 14.11 | 14 | 9836 | 10557 | 79723981 |
| Drug intolerance | 20.27 | 14.11 | 4 | 9846 | 264115 | 79470423 |
| Akathisia | 19.87 | 14.11 | 15 | 9835 | 13244 | 79721294 |
| Tri-iodothyronine decreased | 19.53 | 14.11 | 5 | 9845 | 297 | 79734241 |
| Non-high-density lipoprotein cholesterol increased | 18.93 | 14.11 | 5 | 9845 | 336 | 79734202 |
| Cardiotoxicity | 18.68 | 14.11 | 14 | 9836 | 12225 | 79722313 |
| Rhabdomyolysis | 18.55 | 14.11 | 40 | 9810 | 103091 | 79631447 |
| Myasthenic syndrome | 18.44 | 14.11 | 6 | 9844 | 836 | 79733702 |
| Aspiration | 18.16 | 14.11 | 17 | 9833 | 20141 | 79714397 |
| Syncope | 18.13 | 14.11 | 56 | 9794 | 179393 | 79555145 |
| Renal papillary necrosis | 17.78 | 14.11 | 5 | 9845 | 425 | 79734113 |
| Occipital neuralgia | 17.28 | 14.11 | 5 | 9845 | 471 | 79734067 |
| Muscular dystrophy | 16.93 | 14.11 | 4 | 9846 | 170 | 79734368 |
| Cardiogenic shock | 16.49 | 14.11 | 23 | 9827 | 41891 | 79692647 |
| Acute kidney injury | 16.40 | 14.11 | 115 | 9735 | 519289 | 79215249 |
| Bradycardia | 16.27 | 14.11 | 45 | 9805 | 135512 | 79599026 |
| Phaeochromocytoma | 15.61 | 14.11 | 5 | 9845 | 662 | 79733876 |
| Neuroleptic malignant syndrome | 15.39 | 14.11 | 18 | 9832 | 27541 | 79706997 |
| Electrocardiogram QRS complex shortened | 15.17 | 14.11 | 5 | 9845 | 725 | 79733813 |
| Globulins increased | 15.14 | 14.11 | 5 | 9845 | 730 | 79733808 |
| Activation syndrome | 14.97 | 14.11 | 4 | 9846 | 281 | 79734257 |
| Alopecia | 14.89 | 14.11 | 5 | 9845 | 231350 | 79503188 |
| Hyperlactacidaemia | 14.80 | 14.11 | 9 | 9841 | 5586 | 79728952 |
| Pneumonia salmonella | 14.78 | 14.11 | 3 | 9847 | 62 | 79734476 |
| Blood prolactin increased | 14.75 | 14.11 | 8 | 9842 | 4003 | 79730535 |
| Ventricular extrasystoles | 14.72 | 14.11 | 15 | 9835 | 19689 | 79714849 |
| Feeling abnormal | 14.54 | 14.11 | 48 | 9802 | 159151 | 79575387 |
| Food interaction | 14.32 | 14.11 | 6 | 9844 | 1696 | 79732842 |
| Thyroxine decreased | 14.29 | 14.11 | 5 | 9845 | 868 | 79733670 |
| Fall | 14.25 | 14.11 | 106 | 9744 | 487523 | 79247015 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C02CA01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists |
| ATC | C02LE01 | CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Alpha-adrenoreceptor antagonists and diuretics |
| FDA MoA | N0000000099 | Adrenergic alpha-Antagonists |
| FDA EPC | N0000175553 | alpha-Adrenergic Blocker |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058668 | Adrenergic alpha-1 Receptor Antagonists |
| MeSH PA | D000317 | Adrenergic alpha-Antagonists |
| MeSH PA | D018674 | Adrenergic Antagonists |
| MeSH PA | D000959 | Antihypertensive Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| CHEBI has role | CHEBI:35674 | antihypertensive drugs |
| CHEBI has role | CHEBI:37890 | alpha-adrenergic receptor blockaders |
| CHEBI has role | CHEBI:76779 | post-proline endopeptidase inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypertensive disorder | indication | 38341003 | DOID:10763 |
| Benign prostatic hyperplasia | off-label use | 266569009 | |
| PTSD related nightmares | off-label use | 428687006 | |
| Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares | off-label use | ||
| End stage renal disease | contraindication | 46177005 | DOID:784 |
| Narcolepsy | contraindication | 60380001 | DOID:8986 |
| Cataract surgery | contraindication | 110473004 | |
| Micturition syncope | contraindication | 234168001 | |
| Syncope | contraindication | 271594007 | |
| Intraoperative floppy iris syndrome | contraindication | 418801006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.22 | Basic |
| pKa2 | 0.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1D adrenergic receptor | GPCR | INVERSE AGONIST | Ki | 9.70 | CHEMBL | IUPHAR | |||
| Alpha-1B adrenergic receptor | GPCR | INVERSE AGONIST | Ki | 9.68 | CHEMBL | IUPHAR | |||
| Alpha-1A adrenergic receptor | GPCR | INVERSE AGONIST | Ki | 10.40 | CHEMBL | IUPHAR | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.58 | DRUG MATRIX | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.89 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 9.48 | CHEMBL | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.62 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | IC50 | 9.07 | CHEMBL | |||||
| D(4) dopamine receptor | GPCR | Ki | 5.08 | CHEMBL | |||||
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Enzyme | IC50 | 8.11 | CHEMBL | |||||
| Matrix metalloproteinase-9 | Enzyme | IC50 | 5.16 | DRUG MATRIX | |||||
| Interstitial collagenase | Enzyme | IC50 | 5.39 | DRUG MATRIX | |||||
| Solute carrier family 22 member 1 | Transporter | IC50 | 5 | CHEMBL | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.87 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.80 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 4.42 | CHEMBL | |||||
| Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.68 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.80 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.73 | WOMBAT-PK | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 10 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 10.15 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 9.70 | CHEMBL | |||||
| Mu-type opioid receptor | GPCR | Ki | 9.70 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | IC50 | 4.96 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.63 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.82 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.78 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 9.77 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 5.39 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.97 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 9.08 | CHEMBL | |||||
| Adrenergic receptor alpha-2 | GPCR | Ki | 9.40 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Kd | 10.99 | CHEMBL | |||||
| Serotonin 2 (5-HT2) receptor | GPCR | IC50 | 4.38 | CHEMBL | |||||
| Alpha-2 adrenergic receptor | GPCR | Ki | 7.89 | CHEMBL | |||||
| Beta-casein | Unclassified | Ki | 9.44 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019901 | VUID |
| N0000147986 | NUI |
| D00609 | KEGG_DRUG |
| 19237-84-4 | SECONDARY_CAS_RN |
| 4018850 | VANDF |
| 4019901 | VANDF |
| C0032912 | UMLSCUI |
| CHEBI:8364 | CHEBI |
| XRA | PDB_CHEM_ID |
| CHEMBL2 | ChEMBL_ID |
| CHEMBL1558 | ChEMBL_ID |
| D011224 | MESH_DESCRIPTOR_UI |
| DB00457 | DRUGBANK_ID |
| 503 | IUPHAR_LIGAND_ID |
| 2593 | INN_ID |
| XM03YJ541D | UNII |
| 4893 | PUBCHEM_CID |
| 203210 | RXNORM |
| 2426 | MMSL |
| 5345 | MMSL |
| d00138 | MMSL |
| 000635 | NDDF |
| 004491 | NDDF |
| 387283005 | SNOMEDCT_US |
| 387433003 | SNOMEDCT_US |
| 76058001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Minipress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-4310 | CAPSULE | 1 mg | ORAL | NDA | 22 sections |
| Minipress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-4370 | CAPSULE | 2 mg | ORAL | NDA | 22 sections |
| Minipress | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-4380 | CAPSULE | 5 mg | ORAL | NDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4067 | CAPSULE | 1 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4068 | CAPSULE | 2 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-4069 | CAPSULE | 5 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1101 | CAPSULE | 1 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1101 | CAPSULE | 1 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-1101 | CAPSULE | 1 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2302 | CAPSULE | 2 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2302 | CAPSULE | 2 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2302 | CAPSULE | 2 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3205 | CAPSULE | 5 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3205 | CAPSULE | 5 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-3205 | CAPSULE | 5 mg | ORAL | ANDA | 22 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7020 | CAPSULE | 1 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7020 | CAPSULE | 1 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7021 | CAPSULE | 2 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7021 | CAPSULE | 2 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7022 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7022 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-666 | CAPSULE | 1 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-666 | CAPSULE | 1 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-667 | CAPSULE | 2 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-667 | CAPSULE | 2 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-668 | CAPSULE | 5 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-668 | CAPSULE | 5 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-860 | CAPSULE | 1 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-861 | CAPSULE | 2 mg | ORAL | ANDA | 21 sections |
| Prazosin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43063-248 | CAPSULE | 5 mg | ORAL | ANDA | 22 sections |